Literature DB >> 16606369

Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo.

Angela L Guillozet-Bongaarts1, Michael E Cahill, Vincent L Cryns, Matthew R Reynolds, Robert W Berry, Lester I Binder.   

Abstract

The tangles of Alzheimer's disease (AD) are comprised of the tau protein displaying numerous alterations, including phosphorylation at serine 422 (S422) and truncation at aspartic acid 421 (D421). Truncation at the latter site appears to result from activation of caspases, a class of proteases that cleave specifically at aspartic acid residues. It has been proposed that phosphorylation at or near caspase cleavage sites could regulate the ability of the protease to cleave at those sites. Here, we use tau pseudophosphorylated at S422 (S422E) to examine the effects of tau phosphorylation on its cleavage by caspase 3. We find that S422E tau is more resistant to proteolysis by caspase 3 than non-pseudophosphorylated tau. Additionally, we use antibodies directed against the phosphorylation site and against the truncation epitope to assess the presence of these epitopes in neurofibrillary tangles in the aged human brain. We show that phosphorylation precedes truncation during tangle maturation. Moreover, the distribution of the two epitopes suggests that a significant length of time (perhaps as much as two decades) elapses between S422 phosphorylation and cleavage at D421. We further conclude that tau phosphorylation at S422 may be a protective mechanism that inhibits cleavage in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16606369     DOI: 10.1111/j.1471-4159.2006.03784.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  68 in total

1.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

2.  Alzheimer disease: caspases first.

Authors:  Jesús Avila
Journal:  Nat Rev Neurol       Date:  2010-11       Impact factor: 42.937

3.  Pre-aggregated Aβ1-42 peptide increases tau aggregation and hyperphosphorylation after short-term application.

Authors:  Sabine Ott; Andreas Wolfram Henkel; Maria Kerstin Henkel; Zoran B Redzic; Johannes Kornhuber; Jens Wiltfang
Journal:  Mol Cell Biochem       Date:  2010-11-27       Impact factor: 3.396

4.  Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Authors:  Laetitia Troquier; Raphaelle Caillierez; Sylvie Burnouf; Francisco J Fernandez-Gomez; Marie-Eve Grosjean; Nadege Zommer; Nicolas Sergeant; Susanna Schraen-Maschke; David Blum; Luc Buee
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

5.  Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease.

Authors:  Siddhartha Mondragón-Rodríguez; Gustavo Basurto-Islas; Ismael Santa-Maria; Raúl Mena; Lester I Binder; Jesús Avila; Mark A Smith; George Perry; Francisco García-Sierra
Journal:  Int J Exp Pathol       Date:  2008-04       Impact factor: 1.925

6.  Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease.

Authors:  Chelsea T Tiernan; Stephen D Ginsberg; Bin He; Sarah M Ward; Angela L Guillozet-Bongaarts; Nicholas M Kanaan; Elliott J Mufson; Scott E Counts
Journal:  Neurobiol Dis       Date:  2018-05-31       Impact factor: 5.996

Review 7.  Tau in neurodegenerative disease.

Authors:  Yong-Lei Gao; Nan Wang; Fu-Rong Sun; Xi-Peng Cao; Wei Zhang; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2018-05

Review 8.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

9.  Tau and Axonal Transport Misregulation in Tauopathies.

Authors:  Benjamin Combs; Rebecca L Mueller; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

10.  Modifications of tau protein after cerebral ischemia and reperfusion in rats are similar to those occurring in Alzheimer's disease - Hyperphosphorylation and cleavage of 4- and 3-repeat tau.

Authors:  Hiroki Fujii; Tetsuya Takahashi; Tomoya Mukai; Shigeru Tanaka; Naohisa Hosomi; Hirofumi Maruyama; Norio Sakai; Masayasu Matsumoto
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.